AbCellera, Merck Launch Collaboration
News Jan 29, 2016
AbCellera, a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced a new collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to generate antibodies against an undisclosed disease target.
“Our platform has the potential to generate functional antibodies against extremely difficult targets that have been intractable until now,” says Dr. Carl Hansen, President and CEO of AbCellera. “We’re excited to partner with a global innovator like Merck in the discovery of antibodies to advance their pipeline of next-generation therapies.”
“Merck recognizes the innovative science and synergy of collaboration in British Columbia. Our company has established several life sciences collaborations in the province aimed at translating breakthrough science into products that can bring meaningful improvements to patients' lives,” explained Chirfi Guindo, President and Managing Director at Merck Canada Inc. “We are pleased to be working with AbCellera to identify novel antibodies using their innovative microfluidic discovery technology.”
Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function. The agreement grants Merck the option to develop antibody candidates identified through the collaboration for specified therapeutic applications. Financial terms of the deal were not disclosed.
T Cells Attack and Kill Dopamine-Producing Cells in Parkinson's diseaseNews
Researchers in Germany discover a potential new target for treating Parkinson's diseaseREAD MORE
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE